#1 Clinical Trials Search in Europe

Riboflavin Sodium Phosphate

This article discusses a clinical trial investigating the use of Riboflavin Sodium Phosphate in treating oral ulcers associated with Crohn’s disease. The study compares the effectiveness of Riboflavin Sodium Phosphate with Mesalazine Sustained-Release Tablets, focusing on ulcer healing, symptom relief, and potential side effects. This research aims to provide valuable insights into managing oral complications in Crohn’s disease patients.

Table of Contents

What is Riboflavin Sodium Phosphate?

Riboflavin Sodium Phosphate is a medication that has been studied for its potential benefits in treating oral ulcers associated with Crohn’s disease[1]. Crohn’s disease is a type of inflammatory bowel disease that can affect various parts of the digestive tract, including the mouth. When it affects the mouth, it can cause painful ulcers that interfere with eating and quality of life.

Use in Crohn’s Disease

In a clinical trial, Riboflavin Sodium Phosphate was used specifically to treat oral ulcers in patients with Crohn’s disease[1]. Oral ulcers are open sores that can develop in the mouth and can be a distressing symptom for many Crohn’s disease patients. The study aimed to evaluate how effective and safe this treatment would be for managing these oral lesions.

How is it Applied?

The application of Riboflavin Sodium Phosphate in the study was as follows[1]:

  • The medication comes in the form of an injection, but it is applied topically (on the surface) to the ulcers.
  • It is gently applied directly to the ulcer surface.
  • The treatment is administered three times a day.
  • The specific application times were 8:00 AM, 12:00 PM, and 4:00 PM.

Patients were instructed to measure the size of their mouth ulcers and record their symptoms in a diary card daily at 8:00 PM. This helps track the progress of the treatment and any changes in the ulcers over time.

Efficacy and Outcomes

The study looked at several outcomes to determine how well Riboflavin Sodium Phosphate worked[1]:

  1. Oral ulcer healing: This was the primary outcome of the study. Ulcer healing was categorized into degrees based on the size and number of ulcers:
    • 1st degree: A single ulcer with an area ≤ 8mm
    • 2nd degree: A single ulcer with an area between 8mm and 15mm, or two ulcers each ≤ 8mm
    • 3rd degree: A single ulcer with an area ≥ 15mm, or two ulcers each between 8mm and 15mm
    The treatment was considered effective if the ulcer area decreased by at least one degree.
  2. Ulcer recurrence: The study also observed how often ulcers came back after treatment, looking at a period of 28 days after the end of treatment.
  3. Symptom improvement: This was measured by looking at the frequency and severity of oral pain, loss of appetite, and difficulty eating.

Potential Side Effects

While the study focused on the effectiveness of Riboflavin Sodium Phosphate, it also monitored for potential side effects[1]. Common side effects that were looked for included:

  • Headache
  • Diarrhea
  • Nausea
  • Abdominal pain
  • Vomiting
  • Skin rash

It’s important to note that these were potential side effects being monitored, not necessarily experienced by all patients. Always discuss any side effects with your healthcare provider.

Comparison with Mesalazine

In the clinical trial, Riboflavin Sodium Phosphate was compared to another treatment called Mesalazine (also known as Pentasa)[1]. Mesalazine was used in a different form:

  • It was prepared as a 2.5% suspension by mixing Mesalazine sustained-release tablets with glycerol.
  • This suspension was also applied gently to the ulcer surface three times a day, at the same times as the Riboflavin Sodium Phosphate.

The comparison between these two treatments helps researchers understand which might be more effective for treating oral ulcers in Crohn’s disease patients.

Aspect Details
Study Type Randomized clinical trial
Condition Oral ulcers in Crohn’s disease patients
Interventions 1. Riboflavin Sodium Phosphate Injection
2. Mesalazine Sustained-Release Tablets
Application Method Topical application to ulcer surface, 3 times daily
Treatment Duration 7 days
Follow-up Period 28 days after treatment end
Primary Outcomes 1. Oral ulcer healing
2. Oral ulcer recurrence
Secondary Outcomes 1. Symptom effective rates
2. Adverse events
Measurement Times Daily at 8:00 PM during treatment, end of treatment, and end of follow-up

FAQ

  • What is the purpose of this clinical trial? The purpose of this clinical trial is to evaluate the effectiveness and safety of topically applied Riboflavin Sodium Phosphate in treating oral ulcers in patients with Crohn's disease, comparing it to Mesalazine Sustained-Release Tablets.
  • How is Riboflavin Sodium Phosphate administered in the trial? Riboflavin Sodium Phosphate is gently applied to the ulcer surface three times a day, at 8:00 AM, 12:00 PM, and 4:00 PM.
  • What are the primary outcomes measured in this study? The primary outcomes measured are oral ulcer healing during the 7-day treatment period and oral ulcer recurrence within 28 days after the end of treatment.
  • How is the effectiveness of the treatment determined? The effectiveness is determined by measuring the change in ulcer area and categorizing it into degrees of healing. Recovery means complete healing, effective means a decrease in ulcer area by at least one degree, and invalid means no change in ulcer area.
  • What potential side effects are being monitored in this trial? The study monitors for common side effects including headache, diarrhea, nausea, abdominal pain, vomiting, and skin rash throughout the treatment period and for 28 days after treatment ends.

Ongoing Clinical Trials on Riboflavin Sodium Phosphate

  • Study on Faster Weaning from Ventilators in Critically Ill Patients Using Levosimendan and a Drug Combination

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on the Early Use of Levosimendan Compared to Placebo for Patients with Cardiogenic Shock

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Crohn's Disease: A type of inflammatory bowel disease that can affect any part of the digestive tract, often causing symptoms like abdominal pain, diarrhea, and in some cases, oral ulcers.
  • Oral Ulcer: A sore that develops in the mouth, which can be painful and make eating and speaking difficult.
  • Riboflavin Sodium Phosphate: A form of vitamin B2 used in this study as a topical treatment for oral ulcers in Crohn's disease patients.
  • Mesalazine: An anti-inflammatory drug commonly used to treat inflammatory bowel diseases like Crohn's disease. In this study, it's used in a sustained-release tablet form mixed with glycerol for topical application.
  • Topical Application: A method of applying medication directly to a specific area on the body's surface, in this case, directly to the oral ulcers.
  • Sustained-Release: A drug formulation designed to release the active ingredient slowly over time, providing a prolonged effect.
  • Randomization: The process of randomly assigning participants to different treatment groups to ensure a fair comparison between treatments.
  • Efficacy: The ability of a treatment to produce the desired result under ideal conditions.
  • Remission: A period during which the symptoms of a disease are reduced or disappear.
  • Adverse Events: Unexpected medical problems that happen during a study, which may or may not be caused by the treatment being tested.

References

  1. https://clinicaltrials.gov/study/NCT02769494